InMed Pharmaceuticals Valuation
| INM Stock | USD 5.26 0.11 2.14% |
At this time, the firm appears to be overvalued. InMed Pharmaceuticals retains a regular Real Value of $4.54 per share. The prevalent price of the firm is $5.26. Our model calculates the value of InMed Pharmaceuticals from evaluating the firm fundamentals such as return on asset of -0.39, and Return On Equity of -0.72 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting InMed Pharmaceuticals' valuation include:
Price Book 0.4499 | Enterprise Value -747.9 K | Enterprise Value Ebitda 0.9967 | Price Sales 0.8215 | Trailing PE 0.0228 |
Overvalued
Today
Please note that InMed Pharmaceuticals' price fluctuation is very risky at this time. Calculation of the real value of InMed Pharmaceuticals is based on 3 months time horizon. Increasing InMed Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the InMed stock is determined by what a typical buyer is willing to pay for full or partial control of InMed Pharmaceuticals. Since InMed Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of InMed Stock. However, InMed Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.26 | Real 4.54 | Hype 5.21 | Naive 5.48 |
The intrinsic value of InMed Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence InMed Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of InMed Pharmaceuticals helps investors to forecast how InMed stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of InMed Pharmaceuticals more accurately as focusing exclusively on InMed Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use InMed Pharmaceuticals' intrinsic value based on its ongoing forecasts of InMed Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against InMed Pharmaceuticals' closest peers.
InMed Pharmaceuticals Cash |
|
InMed Valuation Drivers Correlation
Many accounts on the financial statements of InMed Pharmaceuticals are highly interrelated and sometimes correlated. Consequently, when conducting InMed's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of InMed
Click cells to compare fundamentals
InMed Valuation Trend
Knowing InMed Pharmaceuticals' actual value is paramount for traders when making sound investment determinations. Using both InMed Pharmaceuticals' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
InMed Pharmaceuticals Total Value Analysis
InMed Pharmaceuticals is currently estimated to have company total value of (747.91 K) with market capitalization of 3.78 M, debt of 962.66 K, and cash on hands of 9.35 M. The negative valuation of InMed Pharmaceuticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial commitments of the company both on and off balance sheet. Investors should carefully check all of the InMed Pharmaceuticals fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(747.91 K) | 3.78 M | 962.66 K | 9.35 M |
InMed Pharmaceuticals Investor Information
The company has price-to-book (P/B) ratio of 0.45. Some equities with similar Price to Book (P/B) outperform the market in the long run. InMed Pharmaceuticals recorded earning per share (EPS) of 230.4. The entity last dividend was issued on the 6th of July 2020. The firm had 1:20 split on the 14th of November 2024. Based on the key indicators related to InMed Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, InMed Pharmaceuticals may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.InMed Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. InMed Pharmaceuticals has an asset utilization ratio of 38.89 percent. This suggests that the Company is making $0.39 for each dollar of assets. An increasing asset utilization means that InMed Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.InMed Pharmaceuticals Ownership Allocation
Roughly 89.89 (percent) of InMed Pharmaceuticals outstanding shares are held by general public with 0.61 % owned by insiders and only 9.5 pct. by outside corporations.InMed Pharmaceuticals Profitability Analysis
The company reported the last year's revenue of 4.6 M. Reported Net Loss for the year was (7.68 M) with profit before taxes, overhead, and interest of 1.4 M.About InMed Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of InMed Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of InMed Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing InMed Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of InMed Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of InMed Pharmaceuticals. We calculate exposure to InMed Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of InMed Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 1.1 M | 1.2 M | |
| Pretax Profit Margin | (1.67) | (0.72) | |
| Operating Profit Margin | (0.59) | (0.62) | |
| Net Loss | (1.67) | (0.73) | |
| Gross Profit Margin | 0.24 | 0.43 |
InMed Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as InMed Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 7.6 M |
InMed Pharmaceuticals Current Valuation Indicators
InMed Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final InMed Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as InMed Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use InMed Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes InMed Pharmaceuticals' worth.When determining whether InMed Pharmaceuticals is a strong investment it is important to analyze InMed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact InMed Pharmaceuticals' future performance. For an informed investment choice regarding InMed Stock, refer to the following important reports: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 230.4 | Revenue Per Share 0.603 | Quarterly Revenue Growth (0.45) | Return On Assets (0.39) | Return On Equity (0.72) |
The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.